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CLOTTING AND OTHER PLASMA 
FACTORS IN SEPTICEMIA: 
INHIBITION OF DEGRADATION BY 
AN EXOGENOUS PROTEASE 
INHIBITOR FROM SOYBEANS 
(TYPE: BOWMAN-BIRK) 
M. JOCHUM, J. WITTE, H. SCHIESSLER and H. FRITZ 
Department of Clinical Chemistry and Biochemistry, Surgical Ciinic 
University of Munich, Federai Repubiic of Germany 
ABSTRACT 
In the course of Gram-negative s e p t i c e m i a , s e p t i c shock, or e x p e r i -
mental endotoxemia g r a n u l o c y t i c p r o t e i n a s e s such as e l a s t a s e and c a -
t h e p s i n G are suggested to be r e l e a s e d by S t i m u l a t i o n with endotoxin. 
In v i t r o p r o t e o l y s i s of s e v e r a l plasma f a c t o r s by g r a n u l o c y t i c e l a -
s t a s e i s almost completely prevented by p r i o r i n h i b i t i o n of e l a s t a s e 
with a P r o t e i n a s e i n h i b i t o r from soybeans (Bowman-Birk i n h i b i t o r , B B I ) . 
In experimental endotoxemia i n dogs, degradation o f v a r i o u s plasma 
f a c t o r s c o u l d a l s o be s i g n i f i c a n t l y d i m i n i s h e d by p r i o r systemic ap-
p l i c a t i o n o f t h i s e l a s t a s e - c a t h e p s i n G i n h i b i t o r (BBI). These r e s u l t s 
i n d i c a t e t h a t the consumption r e a c t i o n observed d u r i n g endotoxemia 
and se p t i c e m i a i s a b i p h a s i c event. Besides a c t i v a t i o n of the c l o t t i n g 
and f i b r i n o l y t i c Systems by s y s t e m - s p e c i f i c p r o t e i n a s e s such as throm-
bokinase or Plasminogen a c t i v a t o r , the decrease of the l e v e l s of p l a s -
ma f a c t o r s i s caused a l s o to an a p p r e c i a b l e degree by u n s p e c i f i c p ro-
t e o l y t i c degradation due to g r a n u l o c y t i c p r o t e i n a s e s . 
KEYWORDS 
Septicemia; endotoxemia; endotoxin; disseminated i n t r a v a s c u l a r coagu-
l a t i o n (DIC); u n s p e c i f i c p r o t e o l y s i s ; g r a n u l o c y t i c p r o t e i n a s e s ; Pro-
t e i n a s e i n h i b i t o r . 
INTRODUCTION 
Human polymorphonuclear (PMN) leu k o c y t e s c o n t a i n a t l e a s t three neu-
t r a l p r o t e i n a s e s ( e l a s t a s e , c a t h e p s i n G, collagenase) which are r e -
le a s e d by S t i m u l a t i o n with endotoxin. T h i s c o u l d be p a r t i c u l a r l y de-
monstrated f o r g r a n u l o c y t i c e l a s t a s e i n the course of acute myeloic 
leukemia and septicemia (Egbring and co-workers, 1977) as w e l l as i n 
canine endotoxin shock. (Aasen and Ohlsson, 1978). The a c t i v i t i e s of 
c l o t t i n g and other plasma f a c t o r s e i t h e r i n t h e i r i s o l a t e d form or i n 
plasma are s t r o n g l y reduced by d i g e s t i o n with e l a s t a s e or c a t h e p s i n G 
(Johnson and co-workers, 1976; Schmidt and co-workers, 1974). 
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Even i n v i v o the r e d u c t i o n of such f a c t o r s could be due to degrada-
t i o n by g r a n u l o c y t i c p r o t e i n a s e s under c e r t a i n p a t h o l o g i c a l c o n d i -
t i o n s (Egbring and Havemann, 1978). 
The a c t i v i t y o f the g r a n u l o c y t i c p r o t e i n a s e s i s r e g u l a t e d i n v i v o by 
plasma i n h i b i t o r s such as oC* - a n t i t r y p s i n , öC 2-macroglobulin and eC-
a n t i c h y m o t r y p s i n and by a n t i l e u k o p r o t e a s e i n mucous s e c r e t i o n s (ror 
r e f e r e n c e s see Aasen and Ohlsson, 1978). The i n v i t r o i n t e r a c t i o n of 
g r a n u l o c y t i c e l a s t a s e and c a t h e p s i n G with i n h i b i t o r s o f animal, p l a n t 
and m i c r o b i a l o r i g i n i s w e l l i n v e s t i g a t e d ( S c h i e s s l e r and co-workers, 
1977). Only r e c e n t l y , i n h i b i t i o n of g r a n u l o c y t i c p r o t e i n a s e s c o u l d be 
demonstrated i n d i r e c t l y a f t e r a p p l i c a t i o n of an e l a s t a s e - c a t h e p s i n G 
i n h i b i t o r from soybeans (BBI; MW 8000) i n the course of experimental 
Gram-negative septicemia i n dogs ( S c h i e s s l e r and co-workers, 1978). 
As i n f u s i o n of BBI prevented the r a p i d f a l l i n a c t i v i t y o f the f i b -
r i n - s t a b i l i z i n g f a c t o r F X I I I , the authors suggested t h a t t h i s de-
crease might be a l s o caused by n o n s p e c i f i c p r o t e o l y s i s r a t h e r than by 
the a c t i o n of thrombin throughout severe disseminated i n t r a v a s c u l a r 
c o a g u l a t i o n (DIC) which o f t e n complicates the p a t h o p h y s i o l o g i c a l 
events i n s e p t i c e m i a . The purpose of t h i s i n v e s t i g a t i o n was to show 
th a t the decrease i n c l o t t i n g and other plasma f a c t o r s d u r i n g s e p t i -
cemia, s e p t i c shock, or experimental endotoxemia i s not o n l y due to 
DIC (Müller-Berghaus and Lasch, 1975) but a l s o to an a p p r e c i a b l e de-
gree to u n s p e c i f i c p r o t e o l y s i s by g r a n u l o c y t i c p r o t e i n a s e s . 
RESULTS 
In v i t r o , p u r i f i e d human g r a n u l o c y t i c e l a s t a s e degraded i s o l a t e d c l o t -
t i n g f a c t o r s (F V I I , F Xa, F XIII) and the t r a n s p o r t p r o t e i n t r a n s -
f e r r i n r a p i d l y w i t h i n 5-30 minutes even at a molar r a t i o of 2 ( e l a -
stase) to 100 (plasma p r o t e i n ) . T h i s c o u l d be demonstrated by PAG-
e l e c t r o p h o r e s i s and immunoelectrophoresis according to L a u r e l l . Ad-
d i t i o n a l l y , the major i n h i b i t o r of c l o t t i n g f a c t o r s a n t i t h r o m b i n I I I 
i s a l s o r a p i d l y degraded by e l a s t a s e thereby l o o s i n g i t s b i o l o g i c a l 
a c t i v i t y . T h i s was shown by c r o s s e d immunoelectrophoresis as w e l l as 
with an a c t i v i t y assay using the chromogenic Substrate S-2238 from 
DeutscheKabi, München (for d e t a i l e d Information: M. Jochum, H. Lan-
der, and H. F r i t z , manuscript i n p r e p a r a t i o n ) . P r o t e o l y t i c degrada-
t i o n and l o s s of a c t i v i t y was almost completely i n h i b i t e d by p r i o r 
i n c u b a t i o n of e l a s t a s e with BBI. 
The plasma l e v e l s of antithrombin I I I and «sC-macroglobulin as w e l l as 
those of v a r i o u s c l o t t i n g ( f i b r i n o g e n , F X I I I ) , complement (C3, C4) 
and other plasma f a c t o r s ( t r a n s f e r r i n , prealbumin, inter-OC-trypsin 
i n h i b i t o r ) were found to be s i g n i f i c a n t l y decreased i n 18 p a t i e n t s 
s u f f e r i n g from hyperdynamic s e p t i c shock (experimental d e t a i l s are 
g i v e n i n the h a b i l i t a t i o n S c r i p t of Witte, 1979 and are submitted 
f o r p u b l i c a t i o n ) . A s i m i l a r s t a t i s t i c a l l y s i g n i f i c a n t r e d u c t i o n of 
the c o n c e n t r a t i o n s and a c t i v i t i e s of s e v e r a l plasma p r o t e i n s (Pro-
thrombin, antithrombin I I I , f a c t o r F X I I I , Plasminogen, d^-plasmin 
i n h i b i t o r , and complement f a c t o r C3) was observed i n experimental 
endotoxemia i n dogs (M. Jochum, J . Witte, H. S c h i e s s l e r , G. Ruck-
de s c h e l , and H. F r i t z , manuscript i n p r e p a r a t i o n ) . In t h i s model, 
the decrease of the plasma p r o t e i n s was c o n s i d e r a b l e d i m i n i s h e d by 
p r i o r intravenous i n j e c t i o n of the e l a s t a s e - c a t h e p s i n G i n h i b i t o r 
BBI ( F i g . 1). 
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F i g . 1 Plasma l e v e l s of s e v e r a l plasma p r o t e i n s 
during experimental endotoxemia without (a) 
and with (b) Bowman-Birk i n h i b i t o r medi-
c a t i o n . At the Ordinate the percentage of 
the s t a r t i n g plasma l e v e l of each f a c t o r 
i s given. At the a b s c i s s a the experimental 
p e r i o d and the endotoxin i n f u s i o n p e r i o d 
( t h i c k l i n e ) are i n d i c a t e d . For f u r t h e r 
d e t a i l s see Witte, 1979. 
DISCUSSION 
Marked consumption or turnover of plasma P r o t e i n a s e i n h i b i t o r s during 
s e p t i c shock r e f l e c t extensive a c t i v a t i o n of the c l o t t i n g , f i b r i n o -
l y t i c , and complement Systems (summarized as "blood Systems") as w e l l 
as the l i b e r a t i o n of c o n s i d e r a b l e amounts of p r o t e i n a s e s from v a r i o u s 
body c e l l s , e s p e c i a l l y from g r a n u l o c y t e s ( f o r r e f e r e n c e s see F r i t z , 
1980). S y s t e m - s p e c i f i c p r o t e i n a s e s such as Plasminogen a c t i v a t o r and 
thrombokinase a c t i v a t e the blood Systems by s p e c i f i c p r o t e o l y t i c 
c l e a v a g e s , i . e . by proenzyme-» enzyme c o n v e r s i o n . l e a d i n g to severe 
consumption of plasma p r o t e i n s . The r e l e a s e of g r a n u l o c y t i c p r o t e i n -
ases causes furthermore c o n s i d e r a b l e u n s p e c i f i c d egradation of the 
plasma f a c t o r s as c o u l d be demonstrated i n d i r e c t l y by systemic a p p l i -
c a t i o n of an e l a s t a s e - c a t h e p s i n G i n h i b i t o r (BBI) i n the course of 
experimental endotoxemia. However, g u a n t i t a t i o n of the degree of con-
sumption due to u n s p e c i f i c p r o t e o l y s i s i s not f e a s i b l e y e t . The r e s u l t s 
of our experimental and c l i n i c a l s t u d i e s i n d i c a t e c l e a r l y t h a t i n ge-
n e r a l i z e d inflammatory processes l i k e s e p t i c e m i a or s e p t i c shock the 
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r e g u l a t o r y i n h i b i t o r p o t e n t i a l of the organism may be o v e r s t r e s s e d . 
Systemic a p p l i c a t i o n of s u i t a b l e P r o t e i n a s e i n h i b i t o r s may prevent 
a t l e a s t the u n s p e c i f i c degradation of plasma f a c t o r s and t h e r e f o r e 
c o n t r i b u t e to m a i n t a i n the p h y s i o l o g i c a l balance. As medication w i t h 
BBI or other P r o t e i n a s e i n h i b i t o r s i s not p o s s i b l e i n humans u n t i l 
t o x i c o l o g i c a l , pharmacological and c l i n i c a l t r i a l s have been success-
f u l l y e l a b o r a t e d , 'Substitution with a n t i t h r o m b i n I I I and o^-macroglo-
b u l i n i s the method of c h o i c e a t present. 
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